WendyeRaeRobbinsMD
Anesthesiology • South San Francisco, CAPain Medicine, Pediatric Pain Medicine
President & CEO, Blade Therapeutics
Dr. Robbins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
442 Littlefield ave
South San Francisco, CA 94080Phone+1 650-443-7382- Is this information wrong?
Summary
- Dr. Wendye Robbins is President & CEO of Blade Therapeutics, a development stage biotechnology company focused on diseases of fibrosis and neurodegeneration. She has spent her career working along side investors building companies with novel life saving technology from the ground up. She has expertise in translational medicine and small and large molecule development.
From 2004 - 2016, she was priviledged to serve as Clinical Associate Professor in the Department of Anesthesiology and Division of Pain Medicine at Stanford University School of Medicine. She completed post graduate training in anesthesiology and pain medicine at Johns Hopkins University School of Medicine, Department of Anesthesia and Critical Care Medicine. She interned in internal medicine at the Hospital of the University of Pennsylvania. She obtained her MD from the Medical College of Pennsylvania and her BS from the University of California, Haas School of Business. She is boarded in anesthesiology.
Education & Training
Johns Hopkins UniversityFellowship, Pain Medicine, 1994 - 1995- Johns Hopkins UniversityResidency, Anesthesiology, 1991 - 1994
University of Pennsylvania Health SystemInternship, Internal Medicine, 1990 - 1991
MCP-Hahnemann College of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 1994 - 2025
MD State Medical License 1995 - 1995
PA State Medical License 1990 - 1991- American Board of Anesthesiology Anesthesiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Publications & Presentations
PubMed
- 2 citationsComplex management of a patient with refractory primary erythromelalgia lacking a SCN9A mutation.Sarah A. Low, Wendye Robbins, Vivianne L. Tawfik> ;Journal of Pain Research. 2017 Apr 27
- 107 citationsReduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patchAnnika B. Malmberg, Andrew P. Mizisin, Nigel A. Calcutt, Thorsten von Stein, Wendye R. Robbins, Keith R. Bley> ;Pain. 2004 Oct 1
Press Mentions
Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary FibrosisOctober 18th, 2021- Blade Therapeutics Announces Publication of Preclinical Evidence Supporting Neuroprotective Effects of Proprietary Calpain Inhibitor in a Rare Inherited Neurodegenerative DiseaseOctober 7th, 2021
- Blade Therapeutics Announces Positive Data from Preclinical Drug-Drug Interaction Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis (IPF)September 20th, 2021
- Join now to see all
Hospital Affiliations
Stanford Health CarePalo Alto, California
VA Palo Alto Heath CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
